Skip to content
OpenCapital
Get started

Charles River Laboratories CRL Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net at other companies

IQVIA logo
IQVIAIQV
——
Danaher logo
DanaherDHR
——
Fortive logo
FortiveFTV
——

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-4.6%—
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%—
Debt / equity1×+0.1×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's debt instrument, unamortized discount (premium) and debt issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's debt instrument, unamortized discount (premium) and debt issuance costs, net?
Charles River Laboratories (CRL) reported debt instrument, unamortized discount (premium) and debt issuance costs, net of -$11.62M in Q1 2026.
How has Charles River Laboratories's debt instrument, unamortized discount (premium) and debt issuance costs, net changed year-over-year?
Charles River Laboratories's debt instrument, unamortized discount (premium) and debt issuance costs, net increased by 22.6% year-over-year, from -$15.01M to -$11.62M.
What is the long-term trend for Charles River Laboratories's debt instrument, unamortized discount (premium) and debt issuance costs, net?
Over 5 years (2020 to 2025), Charles River Laboratories's debt instrument, unamortized discount (premium) and debt issuance costs, net has grown at a -2.8% compound annual growth rate (CAGR), from -$14.35M to -$12.47M.